Changes: Humulin S

Latest revision as of 23:24, 23 May 2012

Humulin S
R, Neutral by Eli Lilly
short-acting
r-DNA/GE/GM
U40, U100	none
Action in dogs: onset 10-30 minutes, peak 1-5h, duration 4-10h ^[1]
Line: Humulin
Also known as: Huminsulin Normal Humulin C, Humulin R, Humuline R Humuline Regular, Humulin Regular Humulina Regular, Humulin ReliOn R Umuline Rapide, Umuline Regular
Similar to: Insuman Rapid, Winthrop Rapid Actrapid, Novolin R, ReliOn/Novolin R Names of Lilly r-DNA/GE/GM insulins worldwide
Use and Handling:
Shelf Life: 24 months	Type: soluble, clear
When Opened: 28 days room temp.
In Pen: 28 days room temp.
Notes: Protect from light and heat Do Not Freeze, May be used intravenously

21944f — Humulin S-a fast-acting, neutral, soluble insulin. Note package similarity of comparable insulin Insuman Rapid.

UK brand name for Lilly's short-acting r-DNA/GE/GM human insulin. ^[2]^[3]^[4]^[5]

The "S" in the product's name is an abbreviation for "soluble".

It's known in North America as Humulin R, ^[6]^[7] elsewhere as Huminsulin Normal, and can also be referred to as Toronto insulin instead of the R classification.

Both Novo Nordisk ^[8] and Aventis produce comparable insulins.

Novo's names for them are Actrapid ^[9]^[10]^[11] and Novolin R; Aventis' is Insuman Rapid ^[12]^[13] and Winthrop Rapid.

Like all R or neutral insulins, nothing is added (suspensions) to alter the insulin's action or speed. ^[14]

A short-acting, soluble, non-suspended insulin produced from r-DNA/GE/GM, bovine, or porcine sources. From 1921 to the 1930's when PZI was developed, R was the only kind of insulin available.

Rtap — **Human** activity profile for r-DNA/GE/GM R (Regular)/Neutral insulin. See links for dog activity.

While both R/neutral and semilente insulins are considered fast-acting, they differ in a few ways. As above, there's no suspension or buffer ^[15] in R/neutral; it's totally dissolved and soluble, meaning it can safely be used intravenously. ^[16]

The very small insulin particles in semilente insulin are suspended by zinc. ^[15] Semilente is cloudy, has an acetate buffer and cannot be used intravenously.

R/Neutral insulin cannot be reliably mixed with Lente or Ultralente insulins. ^[17]^[18] Semilente can; the ratio of 3 parts semilente insulin to 7 parts ultralente insulin produces Lente insulin. ^[15]

R/Neutral Insulins[]

R/Neutral Insulins
	All Short acting All soluble
Bovine/Beef	Hypurin Bovine Neutral Betasint Bovine Corriente
Bovine/Beef	Iletin R (No longer produced.) Hypurin Vet Neutral (No longer produced.) Insuvet Neutral (No longer produced.)
Bovine/Beef Porcine/Pork	Iletin I R (No longer produced.)
Porcine/Pork	Betasint Porcine Corriente Hypurin Porcine Neutral Hypurin Pork Regular Maxirapid CHO
Porcine/Pork	Pork Actrapid (No longer produced.) Iletin II R (No longer produced.) Leo Neutral (No longer produced.)
R-DNA	Actrapid, Huminsulin Normal Humulin C, Humulin R Humulin Regular, Humulina Regular Humuline R, Humuline Regular Humulin S, Insuman Rapid Novolin R, Umuline Rapide Umuline Regular, Winthrop Rapid Humulin ReliOn R
R-DNA	ReliOn/Novolin R (No longer produced.)

References[]

↑ Insulins. North American Veterinary Conference Clinicians Brief (2006).
↑ Patient Information Leaflet-Humulin S. Eli Lilly.
↑ Humulin S Prescribing Information.
↑ Lilly EU/UK Product Sheet & Time Activity Profiles. Eli Lilly.
↑ Humulin S. Medguides UK.
↑ Humulin R patient leaflet. Eli Lilly.
↑ Humulin R Regular Human Insulin. Revolution Health.
↑ Novolin R. Revolution Health.
↑ Patient Information Leaflet-Actrapid. Novo Nordisk.
↑ Scientific Discussion-Actrapid. EMEA.
↑ Prescribing Novo Insulins.
↑ Patient information Leaflet-Insuman Rapid. Sanofi-Aventis.
↑ Prescribing Insuman Insulins.
↑ Humulin R patient leaflet. Eli Lilly.
↑ ^15.0 ^15.1 ^15.2 DeRuiter, Jack. Insulin Preparations-Regular Insulin. Auburn University. Cite error: Invalid <ref> tag; name "Auburn" defined multiple times with different content Cite error: Invalid <ref> tag; name "Auburn" defined multiple times with different content
↑ Maddison, Jill E.,Page, Stephen W.,Church, David B. (2008). Small Animal Clinical Pharmacology. Saunders Ltd..
↑ Deckert, T. (1980). Intermediate-Acting Insulin Preparations: NPH (Isophane) & Lente. Diabetes Care.
Note--in 1980, there were no r-DNA/GE/GM insulins
↑ Resource Guide. American Diabetes Association (2005).

More Information[]

NACDS-Insulin Chart-Page 2
Leeds NHS UK Insulin Guide
Insulin therapy for dogs and cats Dowling, Patricia, September 1995, Canadian Veterinary Journal
A discussion of regular/neutral/normal insulins.

		Related Pages

Novolin R	Humulin R	Winthrop Rapid	Insuman Rapid	Actrapid

[1] Insulins. North American Veterinary Conference Clinicians Brief (2006).

[2] Patient Information Leaflet-Humulin S. Eli Lilly.

[3] Humulin S Prescribing Information.

[4] Lilly EU/UK Product Sheet & Time Activity Profiles. Eli Lilly.

[5] Humulin S. Medguides UK.

[6] Humulin R patient leaflet. Eli Lilly.

[7] Humulin R Regular Human Insulin. Revolution Health.

[8] Novolin R. Revolution Health.

[9] Patient Information Leaflet-Actrapid. Novo Nordisk.

[10] Scientific Discussion-Actrapid. EMEA.

[11] Prescribing Novo Insulins.

[12] Patient information Leaflet-Insuman Rapid. Sanofi-Aventis.

[13] Prescribing Insuman Insulins.

[14] Humulin R patient leaflet. Eli Lilly.

[Auburn-15] 15.0 ^15.1 ^15.2 DeRuiter, Jack. Insulin Preparations-Regular Insulin. Auburn University. Cite error: Invalid <ref> tag; name "Auburn" defined multiple times with different content Cite error: Invalid <ref> tag; name "Auburn" defined multiple times with different content

[16] Maddison, Jill E.,Page, Stephen W.,Church, David B. (2008). Small Animal Clinical Pharmacology. Saunders Ltd..

[17] Deckert, T. (1980). Intermediate-Acting Insulin Preparations: NPH (Isophane) & Lente. Diabetes Care.
Note--in 1980, there were no r-DNA/GE/GM insulins

[18] Resource Guide. American Diabetes Association (2005).

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

@@ Line 37: / Line 37: @@
 <br clear=left>
-UK brand name for Lilly's short-acting r-DNA/GE/GM human insulin <ref>{{cite web|url=http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=13402 |title=Patient Information Leaflet-Humulin S|publisher=Eli Lilly}}</ref><ref>{{cite web|url=http://web.archive.org/web/20080208084240/http://www.drgc.cwc.net/Care_pathway/Patient_information/Insulin/Humulin_S.htm|title= Humulin S Prescribing Information}}</ref><ref>{{cite web|url=http://www.yorkshirediabetes.com/downloads/1071_LLY_Diabetes_RangeChar.pdf|title= Lilly EU/UK Product Sheet & Time Activity Profiles|publisher=Eli Lilly}}</ref><ref>{{cite web|url=http://medguides.medicines.org.uk/document.aspx?name=Humulin%20S&use=Diabetes |title=Humulin S|publisher=Medguides UK}}</ref>.
+UK brand name for Lilly's short-acting r-DNA/GE/GM human insulin. <ref>{{cite web|url=http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=13402 |title=Patient Information Leaflet-Humulin S|publisher=Eli Lilly}}</ref><ref>{{cite web|url=http://web.archive.org/web/20080208084240/http://www.drgc.cwc.net/Care_pathway/Patient_information/Insulin/Humulin_S.htm|title= Humulin S Prescribing Information}}</ref><ref>{{cite web|url=http://www.yorkshirediabetes.com/downloads/1071_LLY_Diabetes_RangeChar.pdf|title= Lilly EU/UK Product Sheet & Time Activity Profiles|publisher=Eli Lilly}}</ref><ref>{{cite web|url=http://medguides.medicines.org.uk/document.aspx?name=Humulin%20S&use=Diabetes |title=Humulin S|publisher=Medguides UK}}</ref>
 The "S" in the product's name is an abbreviation for "[[soluble]]".
-It's known in North America as [[Humulin R]] <ref>{{cite web|url=http://web.archive.org/web/20061010214428/http://www.fda.gov/cder/foi/label/2003/18780scm078,slr067_Humalog_lbl.pdf |title=Humulin R patient leaflet|publisher=Eli Lilly}}</ref><ref>{{cite web|url=http://www.revolutionhealth.com/drugs-treatments/humulin-r |title=Humulin R Regular Human Insulin|publisher=Revolution Health}}</ref>, elsewhere as [[Huminsulin Normal]], and can also be referred to as [[Toronto insulin]] instead of the [[R]] classification.
+It's known in North America as [[Humulin R]], <ref>{{cite web|url=http://web.archive.org/web/20061010214428/http://www.fda.gov/cder/foi/label/2003/18780scm078,slr067_Humalog_lbl.pdf |title=Humulin R patient leaflet|publisher=Eli Lilly}}</ref><ref>{{cite web|url=http://www.revolutionhealth.com/drugs-treatments/humulin-r |title=Humulin R Regular Human Insulin|publisher=Revolution Health}}</ref> elsewhere as [[Huminsulin Normal]], and can also be referred to as [[Toronto insulin]] instead of the [[R]] classification.
 Both [[Novo Nordisk]] <ref>{{cite web|url=http://www.revolutionhealth.com/drugs-treatments/novolin-r|title= Novolin R|publisher=Revolution Health}}</ref> and [[Aventis]] produce comparable insulins.
@@ Line 47: / Line 47: @@
 Novo's names for them are [[Actrapid]] <ref>{{cite web|url=http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=15204 |title=Patient Information Leaflet-Actrapid|publisher=Novo Nordisk}}</ref><ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000424/WC500021655.pdf|title=Scientific Discussion-Actrapid|publisher=EMEA}}</ref><ref>{{cite web|url=http://web.archive.org/web/20080208084240/http://www.drgc.cwc.net/Care_pathway/Patient_information/Insulin/Novo_insulins.htm |title=Prescribing Novo Insulins}}</ref> and [[Novolin R]]; [[Aventis]]' is [[Insuman Rapid]] <ref>{{cite web|url=http://images2.wikia.nocookie.net/diabetesindogs/images/8/82/Insuman_Rapid_patient_info_leaflet.pdf |title=Patient information Leaflet-Insuman Rapid|publisher=Sanofi-Aventis}}</ref><ref>{{cite web|url=http://web.archive.org/web/20080208084240/http://www.drgc.cwc.net/Care_pathway/Patient_information/Insulin/Insuman_insulins.htm |title=Prescribing Insuman Insulins}}</ref> and [[Winthrop Rapid]].
-Like all R or [[neutral]] insulins, nothing is added (suspensions) to alter the insulin's action or speed <ref>{{cite web|url=http://web.archive.org/web/20061010214428/http://www.fda.gov/cder/foi/label/2003/18780scm078,slr067_Humalog_lbl.pdf |title=Humulin R patient leaflet|publisher=Eli Lilly}}</ref>.
+Like all R or [[neutral]] insulins, nothing is added (suspensions) to alter the insulin's action or speed. <ref>{{cite web|url=http://web.archive.org/web/20061010214428/http://www.fda.gov/cder/foi/label/2003/18780scm078,slr067_Humalog_lbl.pdf |title=Humulin R patient leaflet|publisher=Eli Lilly}}</ref>
 A [[short-acting]], soluble, non-suspended insulin produced from [[r-DNA/GE/GM]], [[bovine]], or [[porcine]] sources. From 1921 to the 1930's when PZI was developed, R was the only kind of insulin available.
 [[Image:Rtap.gif|250px|thumb|left|'''Human''' activity profile for r-DNA/GE/GM R (Regular)/Neutral insulin. See links for dog activity.]]
-While both R/neutral and [[semilente]] insulins are considered [[:Category:Fast-acting|fast-acting]], they differ in a few ways. As above, there's no [[suspension]] or buffer <ref>{{cite web|url=http://www.duc.auburn.edu/~deruija/insulin_preparations.pdf |title=Insulin Preparations-Regular Insulin|author=DeRuiter, Jack|publisher=Auburn University}}</ref> in R/neutral; it's totally dissolved and [[soluble]], meaning it can safely be used [[:Category:Intravenous_use_YES|intravenously]].
+While both R/neutral and [[semilente]] insulins are considered [[:Category:Fast-acting|fast-acting]], they differ in a few ways. As above, there's no [[suspension]] or buffer <ref name=Auburn>{{cite web|url=http://www.duc.auburn.edu/~deruija/insulin_preparations.pdf |title=Insulin Preparations-Regular Insulin|author=DeRuiter, Jack|publisher=Auburn University}}</ref> in R/neutral; it's totally dissolved and [[soluble]], meaning it can safely be used [[:Category:Intravenous_use_YES|intravenously]]. <ref>{{cite web|title=Small Animal Clinical Pharmacology|author=Maddison, Jill E.,Page, Stephen W.,Church, David B.|year=2008|publisher=Saunders Ltd.|isbn=0702028584|page=510|url=http://www.amazon.com/Animal-Clinical-Pharmacology-Maddison-DipVetClinStud/dp/0702028584/ref=sr_1_1?s=books&ie=UTF8&qid=1296451134&sr=1-1}}</ref>
-The very small insulin particles in semilente insulin are suspended by [[Suspension#Zinc_suspension_insulins|zinc]] <ref>{{cite web|url=http://www.duc.auburn.edu/~deruija/insulin_preparations.pdf |title=Insulin Preparations-Lente|author=DeRuiter, Jack|publisher=Auburn University}}</ref>. Semilente is [[cloudy]], has an acetate buffer and cannot be used [[:Category:Intravenous_use_NO|intravenously]].
+The very small insulin particles in semilente insulin are suspended by [[Suspension#Zinc_suspension_insulins|zinc]]. <ref name=Auburn>{{cite web|url=http://www.duc.auburn.edu/~deruija/insulin_preparations.pdf |title=Insulin Preparations-Lente|author=DeRuiter, Jack|publisher=Auburn University}}</ref> Semilente is [[cloudy]], has an acetate buffer and cannot be used [[:Category:Intravenous_use_NO|intravenously]].
-R/Neutral insulin cannot be reliably mixed with [[Lente]] or [[Ultralente]] insulins <ref>{{cite web|url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=7192205 |title=Intermediate-Acting Insulin Preparations: NPH (Isophane) & Lente |author=Deckert, T.|year=1980|publisher=Diabetes Care}}<br>Note--in 1980, there were no [[r-DNA/GE/GM]] insulins </ref><ref>{{cite web|url=http://web.archive.org/web/20080526072116/http://www.diabetes.org/rg2005/insulin.jsp |title=Resource Guide |year=2005|publisher=American Diabetes Association}}</ref>. Semilente can; the ratio of 3 parts [[semilente]] insulin to 7 parts [[ultralente]] insulin produces [[Lente]] insulin <ref>{{cite web|url=http://www.duc.auburn.edu/~deruija/insulin_preparations.pdf |title=Insulin Preparations-Lente Insulin|author=DeRuiter, Jack|publisher=Auburn University}}</ref>.
+R/Neutral insulin cannot be reliably mixed with [[Lente]] or [[Ultralente]] insulins. <ref>{{cite web|url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=7192205 |title=Intermediate-Acting Insulin Preparations: NPH (Isophane) & Lente |author=Deckert, T.|year=1980|publisher=Diabetes Care}}<br>Note--in 1980, there were no [[r-DNA/GE/GM]] insulins </ref><ref>{{cite web|url=http://web.archive.org/web/20080526072116/http://www.diabetes.org/rg2005/insulin.jsp |title=Resource Guide |year=2005|publisher=American Diabetes Association}}</ref> Semilente can; the ratio of 3 parts [[semilente]] insulin to 7 parts [[ultralente]] insulin produces [[Lente]] insulin. <ref name=Auburn>{{cite web|url=http://www.duc.auburn.edu/~deruija/insulin_preparations.pdf |title=Insulin Preparations-Lente Insulin|author=DeRuiter, Jack|publisher=Auburn University}}</ref>
 <br clear=both>
 ==R/Neutral Insulins==
@@ Line 97: / Line 97: @@
 ==References==
+{{Reflist|colwidth=30em}}
-<references/>
 ==More Information==